Home
/
Seres Therapeutics, Inc.
/
Financials
/
Quarterly
Seres Therapeutics, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Seres Therapeutics, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$351.0K
Nov 5, 2025
Q3
2025
Sep 30, 2024
$0
Nov 5, 2025
Q2
2024
Jun 30, 2024
$0
Aug 13, 2024
Q1
2024
Mar 31, 2024
$0
May 8, 2024
Q3
2023
Sep 30, 2023
$310.0K
Nov 2, 2023
Q2
2024
Jun 30, 2023
$126.47M
Aug 13, 2024
Q1
2024
Mar 31, 2023
($522.0K)
May 8, 2024
Q3
2023
Sep 30, 2022
$3.44M
Nov 2, 2023
Q2
2023
Jun 30, 2022
$1.22M
Aug 8, 2023
Q1
2023
Mar 31, 2022
$1.49M
May 9, 2023
Q3
2022
Sep 30, 2021
$126.73M
Nov 2, 2022
Q2
2022
Jun 30, 2021
$5.26M
Aug 3, 2022
Q1
2022
Mar 31, 2021
$5.72M
May 4, 2022
Q3
2021
Sep 30, 2020
$1.42M
Nov 10, 2021
Q2
2021
Jun 30, 2020
$6.05M
Aug 3, 2021
Q1
2021
Mar 31, 2020
$8.19M
May 4, 2021
Q3
2020
Sep 30, 2019
$7.03M
Nov 9, 2020
Q2
2020
Jun 30, 2019
$12.53M
Jul 28, 2020
Q1
2020
Mar 31, 2019
$7.32M
May 7, 2020
Q3
2019
Sep 30, 2018
$9.06M
Nov 5, 2019
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$351.0K
Nov 5, 2025
Q3
2022
Sep 30, 2022
$3.44M
Nov 2, 2022
Q2
2022
Jun 30, 2022
$1.22M
Aug 3, 2022
Q1
2022
Mar 31, 2022
$1.49M
May 4, 2022
Q3
2022
Sep 30, 2021
$126.73M
Nov 2, 2022
Q2
2022
Jun 30, 2021
$5.26M
Aug 3, 2022
Q1
2022
Mar 31, 2021
$4.65M
May 4, 2022
Q3
2021
Sep 30, 2020
$80.0K
Nov 10, 2021
Q2
2021
Jun 30, 2020
$5.19M
Aug 3, 2021
Q1
2021
Mar 31, 2020
$5.46M
May 4, 2021
Q3
2020
Sep 30, 2019
$4.84M
Nov 9, 2020
Q2
2020
Jun 30, 2019
$10.45M
Jul 28, 2020
Q1
2020
Mar 31, 2019
$6.62M
May 7, 2020
Q3
2019
Sep 30, 2018
$8.68M
Nov 5, 2019
Q2
2019
Jun 30, 2018
$4.27M
Aug 6, 2019
Q1
2019
Mar 31, 2018
$3.77M
May 2, 2019
Q2
2018
Jun 30, 2017
$3.01M
Aug 2, 2018
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$8.20M
Nov 5, 2025
Q2
2025
Jun 30, 2025
($19.86M)
Aug 6, 2025
Q3
2025
Jun 30, 2025
($19.86M)
Nov 5, 2025
Q3
2025
Mar 31, 2025
$32.68M
Nov 5, 2025
Q2
2025
Mar 31, 2025
$32.68M
Aug 6, 2025
Q1
2025
Mar 31, 2025
$32.68M
May 7, 2025
Q3
2025
Sep 30, 2024
$88.78M
Nov 5, 2025
Q2
2025
Jun 30, 2024
($32.87M)
Aug 6, 2025
Q3
2025
Jun 30, 2024
($32.87M)
Nov 5, 2025
Q1
2025
Mar 31, 2024
($40.13M)
May 7, 2025
Q2
2025
Mar 31, 2024
($40.13M)
Aug 6, 2025
Q3
2025
Mar 31, 2024
($40.13M)
Nov 5, 2025
Q3
2024
Sep 30, 2023
($47.85M)
Nov 13, 2024
Q2
2024
Jun 30, 2023
$46.55M
Aug 13, 2024
Q3
2024
Jun 30, 2023
$46.55M
Nov 13, 2024
Q1
2024
Mar 31, 2023
($71.17M)
May 8, 2024
Q2
2024
Mar 31, 2023
($71.17M)
Aug 13, 2024
Q3
2024
Mar 31, 2023
($71.17M)
Nov 13, 2024
Q3
2023
Sep 30, 2022
($60.00M)
Nov 2, 2023
Q3
2023
Jun 30, 2022
($64.74M)
Nov 2, 2023
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($22.48M)
Nov 5, 2025
Q2
2025
Jun 30, 2025
($24.88M)
Aug 6, 2025
Q1
2025
Mar 31, 2025
($27.24M)
May 7, 2025
Q3
2025
Sep 30, 2024
($29.17M)
Nov 5, 2025
Q2
2025
Jun 30, 2024
($28.87M)
Aug 6, 2025
Q1
2025
Mar 31, 2024
($34.44M)
May 7, 2025
Q3
2024
Sep 30, 2023
($44.59M)
Nov 13, 2024
Q2
2024
Jun 30, 2023
$49.52M
Aug 13, 2024
Q1
2024
Mar 31, 2023
($70.57M)
May 8, 2024
Q3
2023
Sep 30, 2022
($59.11M)
Nov 2, 2023
Q2
2023
Jun 30, 2022
($63.33M)
Aug 8, 2023
Q1
2023
Mar 31, 2022
($55.75M)
May 9, 2023
Q3
2022
Sep 30, 2021
$68.41M
Nov 2, 2022
Q2
2022
Jun 30, 2021
($48.14M)
Aug 3, 2022
Q1
2022
Mar 31, 2021
($35.33M)
May 4, 2022
Q3
2021
Sep 30, 2020
($30.00M)
Nov 10, 2021
Q2
2021
Jun 30, 2020
($20.55M)
Aug 3, 2021
Q1
2021
Mar 31, 2020
($19.69M)
May 4, 2021
Q3
2020
Sep 30, 2019
($17.18M)
Nov 9, 2020
Q2
2020
Jun 30, 2019
($10.95M)
Jul 28, 2020